Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 13,133 Shares

by · The Cerbat Gem

Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) CEO Richard Nolan Townsend sold 13,133 shares of the stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $117,409.02. Following the sale, the chief executive officer owned 242,118 shares in the company, valued at $2,164,534.92. The trade was a 5.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Richard Nolan Townsend also recently made the following trade(s):

  • On Monday, August 18th, Richard Nolan Townsend sold 2,735 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $4.67, for a total transaction of $12,772.45.

Lexeo Therapeutics Trading Up 9.2%

NASDAQ LXEO opened at $9.58 on Friday. The firm’s 50 day simple moving average is $5.91 and its 200 day simple moving average is $4.39. The firm has a market capitalization of $517.32 million, a price-to-earnings ratio of -2.94 and a beta of 1.66. Lexeo Therapeutics, Inc. has a 1 year low of $1.45 and a 1 year high of $11.72.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.04. On average, equities research analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LXEO has been the topic of several research analyst reports. Oppenheimer initiated coverage on Lexeo Therapeutics in a research note on Thursday, July 31st. They issued an “outperform” rating and a $20.00 price objective on the stock. Guggenheim started coverage on shares of Lexeo Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $30.00 price target on the stock. Leerink Partners upped their price objective on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Finally, Chardan Capital raised their target price on shares of Lexeo Therapeutics from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.86.

Get Our Latest Report on LXEO

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. CWM LLC boosted its position in Lexeo Therapeutics by 82.2% during the 3rd quarter. CWM LLC now owns 18,864 shares of the company’s stock worth $125,000 after buying an additional 8,513 shares during the period. Vestal Point Capital LP raised its stake in shares of Lexeo Therapeutics by 184.1% during the second quarter. Vestal Point Capital LP now owns 3,228,161 shares of the company’s stock valued at $12,977,000 after acquiring an additional 2,091,912 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its holdings in shares of Lexeo Therapeutics by 363.1% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company’s stock worth $17,787,000 after purchasing an additional 3,469,210 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Lexeo Therapeutics by 20.4% in the second quarter. BNP Paribas Financial Markets now owns 48,434 shares of the company’s stock worth $195,000 after purchasing an additional 8,223 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its holdings in Lexeo Therapeutics by 39.1% in the second quarter. Bridgeway Capital Management LLC now owns 53,400 shares of the company’s stock valued at $215,000 after purchasing an additional 15,000 shares during the period. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

(Get Free Report)

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

See Also